Sunday, January 19, 2020 7:49:09 AM
Ph 2 is going well. The science is solid.
Another company have success with the science just underscores that PDT treatments are the next huge thing in cancer treatments.
Theralase Researchers Receive Recognition for Recent Scientific Publications November 27, 2019
The recognition from three scientific institutes emphasizes the strong science-based technology that the Company possesses, verifying that Theralase’s Ruthenium-based PDCs are leading the pack in terms of performance of Photo Dynamic Therapy (“PDT”) metal based PDCs to become the next viable option for treating various cancers, suggesting a major change in the way various cancers are treated in the future.
The review article, titled “Metal-Based photosensitizers for photodynamic therapy – the future of multimodal oncology?”, is available online at www.sciencedirect.com and will be published in a special issue of Current Opinion in Chemical Biology entitled Next Generation Therapeutics, Volume 56, June 2020. The article verifies that the Company’s lead PDC TLD-1433 has strong scientific support, is highly advanced in clinical studies and may become the next “gold standard” cancer treatment.
https://theralase.com/pressrelease/theralase-researchers-receive-recognition-for-recent-scientific-publications/
Another company have success with the science just underscores that PDT treatments are the next huge thing in cancer treatments.
Theralase Researchers Receive Recognition for Recent Scientific Publications November 27, 2019
The recognition from three scientific institutes emphasizes the strong science-based technology that the Company possesses, verifying that Theralase’s Ruthenium-based PDCs are leading the pack in terms of performance of Photo Dynamic Therapy (“PDT”) metal based PDCs to become the next viable option for treating various cancers, suggesting a major change in the way various cancers are treated in the future.
The review article, titled “Metal-Based photosensitizers for photodynamic therapy – the future of multimodal oncology?”, is available online at www.sciencedirect.com and will be published in a special issue of Current Opinion in Chemical Biology entitled Next Generation Therapeutics, Volume 56, June 2020. The article verifies that the Company’s lead PDC TLD-1433 has strong scientific support, is highly advanced in clinical studies and may become the next “gold standard” cancer treatment.
https://theralase.com/pressrelease/theralase-researchers-receive-recognition-for-recent-scientific-publications/
Recent TLTFF News
- Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update • Newsfile • 05/04/2026 09:22:00 PM
- Theralase(R) Closes $CAN 2.66 Million Financing • Newsfile • 04/10/2026 11:00:00 AM
- Theralase(R) Closes $1.1 M Non-Brokered Private Placement • Newsfile • 03/10/2026 11:00:00 AM
- Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer • Newsfile • 03/09/2026 11:00:00 AM
- Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress • Newsfile • 02/20/2026 12:00:00 PM
- Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress • Newsfile • 02/17/2026 12:00:00 PM
- Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting • Newsfile • 02/10/2026 12:00:00 PM
- Theralase(R) Provides Update on Bladder Cancer Clinical Study • Newsfile • 02/04/2026 12:00:00 PM
- Theralase and Ferring ink deal for new bladder cancer study • IH Market News • 01/14/2026 11:05:00 AM
- New Bladder Cancer Collaboration Sparks Sharp Rally in This Micro Cap Stock • AllPennyStocks.com • 01/12/2026 03:23:00 PM
- Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer • Newsfile • 01/12/2026 12:00:00 PM
- Theralase(R) Closes $1.3 M Non-Brokered Private Placement • Newsfile • 12/23/2025 09:40:00 PM
- Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing • Newsfile • 12/12/2025 10:00:00 PM
- Theralase(R) Investor Conference Call Reminder • Newsfile • 11/17/2025 12:00:00 PM
- Theralase(R) Releases 3Q2025 Financial Statements • Newsfile • 11/10/2025 12:00:00 PM
- Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus • Newsfile • 09/24/2025 11:00:00 AM
